CA3262258A1 — Combination drug
Assigned to Chugai Pharmaceutical Co Ltd · Expires 2025-06-12 · 1y expired
What this patent protects
The present invention relates to a therapeutic or prophylactic drug, a combination, a pharmaceutical composition, a preparation, a therapeutic or prophylactic method, and a growth suppressor for ALK fusion gene-positive cancer having temporary tolerance to ALK inhibitors, all of …
USPTO Abstract
The present invention relates to a therapeutic or prophylactic drug, a combination, a pharmaceutical composition, a preparation, a therapeutic or prophylactic method, and a growth suppressor for ALK fusion gene-positive cancer having temporary tolerance to ALK inhibitors, all of which act against ALK fusion gene-positive cancer and involve combining an ALK inhibitor and a TNKS inhibitor or further combining with a pan-HER inhibitor.
Drugs covered by this patent
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.